Study wrapper · #889
Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs.
Bitar ER, Besir K, Cummins KC, et al. Journal of gastrointestinal surgery. 2026.
DOI: 10.1016/j.gassur.2026.102497PubMed: 42447648
Editor's note
This large TriNetX cohort compared semaglutide and tirzepatide users against bariatric surgery and other weight-loss drugs, finding therapeutic-dose use associated with lower colorectal and pancreatic cancer incidence and no increased cancer risk. Both tracked peptides are genuine subjects. As a retrospective, propensity-matched study it supports safety reassurance but cannot prove causation, and any-dose effects were not significant.
Plain-language abstract
In a large retrospective cohort of nondiabetic adults with obesity, therapeutic-dose semaglutide or tirzepatide use was associated with lower rates of colorectal and pancreatic cancer than bariatric surgery, with no signal of increased cancer risk.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026